$HLF earnings report

Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion. AlphAI read Herbalife's Third Quarter 2026 filing as solid. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readHLF · Third Quarter 2026 · ended September 30, 2026

Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion

✓Solid quarter

Third-quarter net sales grew 6.0% and adjusted EBITDA margin expanded 70 basis points year-over-year, while operating cash flow was $151.3 million and full-year net sales guidance was increased. China net sales declined 22.0%, EMEA declined 4.9%, and gross margin declined to 77.3% from 77.7%.

Revenue
$1.35B
6.0% y/y
North America, Q3 2026
$268M
1.7% y/y
EPS · non-GAAP
$0.64
$0.14 y/y
Fourth Quarter 2026 and Full-Year 2026 outlook
Fourth Quarter 2026 reported net sales: +0.5% to +4.5% YoY; Fourth Quarter 2026 constant currency net sales: +2.5% to +6.5% YoY; Full-Year 2026 reported net sales: +4.9% to +5.9% YoY; Full-Year 2026 constant currency net sales: +5.3% to +6.3% YoY

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended September 30, 2026GAAP$1.35B–6.0%
Net sales, nine months ended September 30, 2026GAAP$3.99B–6.4%
Net sales growth excluding FX, three months ended September 30, 2026non-GAAP7.6%–7.6%
Gross profit, three months ended September 30, 2026GAAP$1.04B––
Gross profit, nine months ended September 30, 2026GAAP$3.10B––
Gross profit margin, third quarter 2026GAAP77.3%––
Selling expenses, three months ended September 30, 2026GAAP$473.5M––
Selling expenses, nine months ended September 30, 2026GAAP$1.40B––
General and administrative expenses, three months ended September 30, 2026GAAP$432.1M––
General and administrative expenses, nine months ended September 30, 2026GAAP$1.30B––
Operating income, three months ended September 30, 2026GAAP$138.5M––
Operating income, nine months ended September 30, 2026GAAP$405.2M––
Interest expense, net, three months ended September 30, 2026GAAP$31.9M––
Interest expense, net, nine months ended September 30, 2026GAAP$116.1M––
Net income attributable to Herbalife, three months ended September 30, 2026GAAP$58.8M––
Net income attributable to Herbalife, nine months ended September 30, 2026GAAP$94.4M––
Net income margin, third quarter 2026GAAP4.4%––
Adjusted net income, three months ended September 30, 2026non-GAAP$68.5M––
Adjusted net income, nine months ended September 30, 2026non-GAAP$190.8M––
Diluted earnings per share attributable to Herbalife, three months ended September 30, 2026GAAP$0.55–$0.13
Diluted earnings per share attributable to Herbalife, nine months ended September 30, 2026GAAP$0.88––
Adjusted diluted earnings per share, three months ended September 30, 2026non-GAAP$0.64–$0.14
Adjusted diluted earnings per share, nine months ended September 30, 2026non-GAAP$1.77––
Adjusted EBITDA, third quarter 2026non-GAAP$182.4M––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$524.7M––
Adjusted EBITDA margin, third quarter 2026non-GAAP13.5%–up 70 basis points
Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP13.1%––
Adjusted EBITDA at constant currency, third quarter 2026non-GAAP$193.4M––
Credit Agreement EBITDA, third quarter 2026non-GAAP$198.9M––
Net cash provided by operating activities, three months ended September 30, 2026GAAP$151.3M––
Net cash provided by operating activities, nine months ended September 30, 2026GAAP$298M–$63.0 million
Capital expenditures, three months ended September 30, 2026GAAP$18.5M––
Capital expenditures, nine months ended September 30, 2026GAAP$40.7M––

Segments

SegmentRevenueq/qy/y
North America, Q3 2026Second consecutive quarter of year-over-year growth.$267.5M–1.7%
Latin America, Q3 2026Net sales growth excluding FX was 5.1%.$250.2M–9.0%
EMEA, Q3 2026Net sales growth excluding FX was (5.2)%.$259M–(4.9)%
Asia Pacific, Q3 2026Net sales growth excluding FX was 26.1%.$517.9M–18.4%
China, Q3 2026Net sales growth excluding FX was (26.4)%.$55.6M–(22.0)%
Worldwide, Q3 2026Growth was primarily driven by increased sales volume and included 160 basis points of FX headwinds.$1.35B–6.0%
North America, YTD 2026Net sales growth excluding FX was (0.3)%.$788.1M–(0.2)%
Latin America, YTD 2026Net sales growth excluding FX was 6.6%.$737.2M–14.0%
EMEA, YTD 2026Net sales growth excluding FX was (5.8)%.$811.6M–(2.6)%
Asia Pacific, YTD 2026Net sales growth excluding FX was 23.4%.$1.48B–17.0%
China, YTD 2026Net sales growth excluding FX was (24.3)%.$173M–(19.9)%
Worldwide, YTD 2026Net sales growth excluding FX was 6.3%.$3.99B–6.4%

Fourth Quarter 2026 and Full-Year 2026 outlook

  • RevenueFourth Quarter 2026 reported net sales: +0.5% to +4.5% YoY; Fourth Quarter 2026 constant currency net sales: +2.5% to +6.5% YoY; Full-Year 2026 reported net sales: +4.9% to +5.9% YoY; Full-Year 2026 constant currency net sales: +5.3% to +6.3% YoY
  • Tax rateAdjusted effective tax rate of approximately 35%
  • NoteFourth Quarter 2026 adjusted EBITDA: $145 million to $165 million
  • NoteFourth Quarter 2026 constant currency adjusted EBITDA: $155 million to $175 million
  • NoteFourth Quarter 2026 CapEx: $13 million to $23 million
  • NoteFull-Year 2026 adjusted EBITDA: $670 million to $690 million
  • NoteFull-Year 2026 constant currency adjusted EBITDA: $700 million to $720 million
  • NoteFull-Year 2026 CapEx: $55 million to $65 million
  • NoteCapitalized and prepaid SaaS implementation costs of $35 million to $45 million
  • NoteDepreciation and amortization, and amortization of SaaS implementation costs, of $135 million to $145 million

Capital returns

  • Board authorized a new share repurchase program of up to $250 million over three years.
  • No shares were repurchased under the program during the third quarter.
  • Share repurchases were $10.2 million for the nine months ended September 30, 2026.

What drove it

  • Third-quarter net sales growth was primarily driven by increased sales volume.
  • Asia Pacific net sales grew 18.4% on a reported basis and 26.1% excluding FX.
  • Latin America net sales grew 9.0% on a reported basis.
  • The April refinancing reduced net interest expense by $19.1 million year-over-year in the third quarter.
  • Adjusted EBITDA included approximately $11.3 million of FX headwinds year-over-year.

Concerns

  • China net sales declined 22.0% year-over-year, or 26.4% excluding FX, in the third quarter.
  • EMEA net sales declined 4.9% year-over-year, or 5.2% excluding FX, in the third quarter.
  • Gross profit margin declined to 77.3% from 77.7%, primarily due to sales mix pressure and cost changes related to self-manufacturing and sourcing.
  • Third-quarter adjusted diluted EPS included a $0.06 year-over-year FX headwind.
  • John DeSimone was appointed interim CEO effective November 1, 2026, while the Board continues its search for the next Chief Executive Officer.

What to watch

  • Fourth-quarter reported net sales guidance of +0.5% to +4.5% YoY and constant currency net sales guidance of +2.5% to +6.5% YoY.
  • Fourth-quarter adjusted EBITDA guidance of $145 million to $165 million and constant currency adjusted EBITDA guidance of $155 million to $175 million.
  • The execution of the up to $250 million share repurchase program, which is expected to begin in the fourth quarter.
  • The progression of China and EMEA net sales declines.
  • Full-year capitalized and prepaid SaaS implementation costs expected to be approximately $35 million to $45 million, which are not included in capital expenditures.

Balance sheet and cash flow

  • Cash and cash equivalents were $409.2 million as of September 30, 2026.
  • Total debt was $2.0 billion as of September 30, 2026.
  • Net debt was $1,542.7 million as of September 30, 2026.
  • Net leverage ratio was 2.0x as of September 30, 2026, compared to 2.2x as of June 30, 2026.
  • Credit Agreement total leverage ratio was 2.6x as of September 30, 2026, compared to 2.8x as of December 31, 2025.
  • Net cash provided by operating activities was $298.0 million for the nine months ended September 30, 2026, compared to $235.0 million in the prior-year period.
  • Purchases of property, plant and equipment were $40.7 million for the nine months ended September 30, 2026.
  • Net cash used in financing activities was $170.7 million for the nine months ended September 30, 2026.

Analysis

Herbalife reported third-quarter net sales of $1,350.2 million, up 6.0% year-over-year, and said growth was primarily driven by increased sales volume. Net sales increased 7.6% on a constant currency basis, with 160 basis points of FX headwinds. This marked the fifth consecutive quarter of year-over-year net sales growth on both a reported and constant currency basis. Asia Pacific was the principal growth contributor, with reported net sales up 18.4%, while Latin America grew 9.0% and North America grew 1.7%.

Regional performance remained uneven. China net sales fell 22.0% on a reported basis and 26.4% excluding FX, while EMEA declined 4.9% reported and 5.2% excluding FX. North America posted its second consecutive quarter of year-over-year growth, but its year-to-date net sales remained down 0.2%. These regional declines remain important offsets to the acceleration in Asia Pacific and Latin America.

Profitability improved below gross profit despite gross margin declining to 77.3% from 77.7%. The company attributed the gross-margin decline primarily to sales mix pressure and cost changes related to self-manufacturing and sourcing, partially offset by pricing benefits. Adjusted EBITDA rose to $182.4 million and adjusted EBITDA margin reached 13.5%, up 70 basis points year-over-year. Net income attributable to Herbalife was $58.8 million, adjusted net income was $68.5 million, diluted EPS was $0.55, and adjusted diluted EPS was $0.64. The April refinancing reduced third-quarter net interest expense by $19.1 million year-over-year.

Cash generation and leverage improved. Net cash provided by operating activities was $151.3 million in the quarter and $298.0 million year to date, up $63.0 million from the prior-year nine-month period. Cash and cash equivalents were $409.2 million, total debt was $2.0 billion, and the net leverage ratio was 2.0x as of September 30, 2026, compared with 2.2x as of June 30, 2026. The Board authorized a new share repurchase program of up to $250 million over three years, with execution expected to begin in the fourth quarter.

The company guided fourth-quarter reported net sales growth of +0.5% to +4.5% year-over-year and adjusted EBITDA of $145 million to $165 million. Full-year reported net sales guidance was revised to +4.9% to +5.9% year-over-year, while full-year reported adjusted EBITDA guidance was maintained at $670 million to $690 million. Management also increased full-year constant currency adjusted EBITDA guidance to $700 million to $720 million. The guide places attention on sustaining growth outside China and EMEA, protecting margins amid sales mix and sourcing costs, and converting operating momentum into cash while beginning shareholder returns.

Management, verbatim

Third quarter net sales and adjusted EBITDA both exceeded guidance, and adjusted EBITDA margin expanded 70 basis points year-over-year.

Scott Schaefer, CFO

Our April refinancing reduced net interest expense by $19.1 million year-over-year in the third quarter, strengthening our earnings and cash generation.

Scott Schaefer, CFO

We delivered a fifth consecutive quarter of year-over-year net sales growth, and we continue to expect net sales growth for the remainder of the year.

John DeSimone, Interim CEO

Not in the filing

stated, not guessed
  • Free cash flow was not reported.
  • Third-quarter free cash flow and prior-year comparison were not reported.
  • Third-quarter operating income margin was not reported.
  • Quarterly cash flow from financing activities was not reported.
  • Fourth-quarter gross margin guidance was not reported.
  • Fourth-quarter operating expense guidance was not reported.
  • Fourth-quarter tax rate guidance was not reported.
  • Full-year GAAP net income guidance and GAAP EPS guidance were not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readHLF · Second Quarter 2026 · ended June 30, 2026

Herbalife Reports Second Quarter Net Sales Growth; Marks Fourth Consecutive Quarter of Topline Expansion; Net Sales and Adjusted EBITDA Exceed Guidance Excluding FX Headwinds

→Mixed quarter

Net sales grew 5.4% year-over-year and adjusted EBITDA reached the upper end of guidance, but adjusted EBITDA margin declined 120 basis points, GAAP results included a $(26.3) million net loss following a $94.6 million loss on extinguishment of debt, and reported full-year adjusted EBITDA guidance was reduced to $670 million to $690 million from $675 million to $705 million.

Revenue
$1.33B
5.4 % y/y
North America
$273M
0.2 % y/y
EPS · non-GAAP
$ 0.51
Third Quarter 2026 and Full-Year 2026 outlook
Third Quarter 2026 reported net sales: +0.5% to +4.5% YoY; constant currency net sales: +1.5% to +5.5% YoY. Full-Year 2026 revised reported net sales: +2.5% to +5.5% YoY; constant currency net sales: +2.5% to +5.5% YoY.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net salesGAAP$1.33B–5.4 %
Net sales, constant currencynon-GAAP5.8% year-over-year–5.8%
Cost of salesGAAP$296.3M––
Gross profitGAAP$1.03B––
Gross profit marginGAAP77.7%––
Selling expensesGAAP$466M––
General and administrative expensesGAAP$436.2M––
Operating incomeGAAP$128.3M––
Interest expense, netGAAP$37.4M––
Loss on extinguishment of debtGAAP$94.6M––
Net loss attributable to HerbalifeGAAP−$26.3M––
Net loss marginGAAP-2.0 %––
Diluted loss per share attributable to HerbalifeGAAP$ (0.25)––
Adjusted net incomenon-GAAP$53.3M––
Adjusted diluted earnings per sharenon-GAAP$ 0.51––
Adjusted EBITDAnon-GAAP$166.6M––
Adjusted EBITDA marginnon-GAAP12.6 %–down 120 basis points versus the second quarter of 2025
Adjusted EBITDA, constant currencynon-GAAP$174.4M––
Credit Agreement EBITDAnon-GAAP$190.7M––
Net cash provided by operating activitiesGAAP$32.9M––
Capital expendituresother$11.3M––
Six-month net salesGAAP$2.64B–6.6 %
Six-month net income attributable to HerbalifeGAAP$35.6M––
Six-month adjusted net incomenon-GAAP$122.3M––
Six-month adjusted EBITDAnon-GAAP$342.3M––
Six-month net cash provided by operating activitiesGAAP$146.7M––
Six-month capital expendituresother$22.2M––

Segments

SegmentRevenueq/qy/y
North AmericaNet sales were up slightly; excluding FX growth was 0.2 %.$273M–0.2 %
Latin AmericaExcluding FX, net sales growth was 8.2 %.$245M–16.6 %
EMEAExcluding FX, net sales declined (5.6 )%.$277.8M–(3.5 )%
Asia PacificExcluding FX, net sales growth was 23.1 %.$470.6M–15.2 %
ChinaExcluding FX, net sales declined (29.0 )%.$60.4M–(24.5 )%
WorldwideExcluding FX, net sales growth was 5.8 %.$1.33B–5.4 %

Third Quarter 2026 and Full-Year 2026 outlook

  • RevenueThird Quarter 2026 reported net sales: +0.5% to +4.5% YoY; constant currency net sales: +1.5% to +5.5% YoY. Full-Year 2026 revised reported net sales: +2.5% to +5.5% YoY; constant currency net sales: +2.5% to +5.5% YoY.
  • Tax rateFull-Year 2026 adjusted effective tax rate of approximately 35%.
  • NoteThird Quarter 2026 adjusted EBITDA: $160 million – $180 million; constant currency adjusted EBITDA: $165 million – $185 million.
  • NoteThird Quarter 2026 CapEx: $15 million – $25 million.
  • NoteFull-Year 2026 revised adjusted EBITDA: $670 million – $690 million; constant currency adjusted EBITDA: $690 million – $710 million.
  • NoteFull-Year 2026 CapEx: $50 million – $70 million.
  • NoteFull-Year 2026 capitalized SaaS implementation costs: $35 million to $55 million, which are not included in capital expenditures.
  • NoteFull-Year 2026 depreciation and amortization, and amortization of SaaS implementation costs: $140 million to $150 million.
  • NoteNet sales and adjusted EBITDA use the average daily exchange rates for the first two weeks of July 2026 to translate local currency projections.

Capital returns

  • Share repurchases of $10.0 million for the six months ended June 30, 2026.

What drove it

  • Fourth consecutive quarter of year-over-year net sales growth on both a reported and constant currency basis.
  • Latin America and Asia Pacific reported double-digit net-sales growth, while North America net sales were up slightly.
  • Bioniq GO launched across eleven European markets in June and North America in July, with automatic monthly deliveries available in newly-launched European markets.
  • The Company launched Helio and Activate Energy under the Life I/O healthy lifespan brand.
  • The North America Pro2col™ extended beta introduced a new user experience, enhanced features, and blood-test diagnostic integration.
  • Pricing benefits of 64 basis points partially offset gross-margin pressure from sales mix, other costs, inventory write-downs, and self-manufacturing and sourcing costs.
  • Interest expense, net was $ 37.4 million, compared to $ 53.6 million in the prior-year period.

Concerns

  • China net sales were $ 60.4 million, down (24.5 )% year-over-year, and declined (29.0 )% excluding FX.
  • EMEA net sales were $ 277.8 million, down (3.5 )% year-over-year, and declined (5.6 )% excluding FX.
  • Gross profit margin was 77.7%, compared to 78.0% in the prior-year period.
  • Adjusted EBITDA margin was 12.6%, down 120 basis points versus the second quarter of 2025.
  • The $94.6 million loss on extinguishment of debt resulted in net loss attributable to Herbalife of $ (26.3) million.
  • Reported full-year adjusted EBITDA guidance was reduced to $670 million to $690 million from $675 million to $705 million, primarily reflecting FX headwinds.
  • John DeSimone will retire effective December 31, 2026.

What to watch

  • Third-quarter reported net sales guidance of +0.5% to +4.5% YoY and constant currency net sales guidance of +1.5% to +5.5% YoY.
  • Third-quarter adjusted EBITDA guidance of $160 million – $180 million and constant currency adjusted EBITDA guidance of $165 million – $185 million.
  • The impact of FX on reported back-half results, following the strengthening of the U.S. dollar.
  • The performance of China and EMEA, where second-quarter reported net sales declined.
  • Gross-margin effects from sales mix, other costs, inventory write-downs, self-manufacturing and sourcing, and pricing.
  • Execution of Bioniq GO, Pro2col™ and at-home blood biomarker diagnostics initiatives.
  • Scott Schaefer's succession as CFO effective January 1, 2027.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 370.5 million as of June 30, 2026, compared to $ 353.1 million as of December 31, 2025.
  • Credit Agreement total debt was $ 2,039.6 million as of June 30, 2026, compared to $ 2,050.0 million as of December 31, 2025.
  • Net debt was $ 1,669.1 million as of June 30, 2026, compared to $ 1,696.9 million as of December 31, 2025.
  • Credit Agreement total leverage ratio was 2.7x as of June 30, 2026, compared to 2.8x as of December 31, 2025.
  • Net leverage ratio was 2.2x as of June 30, 2026, compared to 2.3x as of December 31, 2025.
  • Long-term debt, net of current portion, was $ 2,003.7 million as of June 30, 2026, compared to $ 1,971.7 million as of December 31, 2025.
  • Net cash provided by operating activities was $ 146.7 million for the six months ended June 30, 2026, compared to $ 96.2 million for the six months ended June 30, 2025.
  • Net cash used in investing activities was $ (32.8) million for the six months ended June 30, 2026, compared to $ (69.4) million for the six months ended June 30, 2025.
  • Net cash used in financing activities was $ (80.7) million for the six months ended June 30, 2026, compared to $ (132.4) million for the six months ended June 30, 2025.

Analysis

Herbalife reported second-quarter net sales of $1.3 billion, up 5.4% year-over-year, or 5.8% on a constant currency basis. This marked its fourth consecutive quarter of reported and constant-currency year-over-year sales growth. Asia Pacific and Latin America were the principal regional growth contributors, with reported growth of 15.2% and 16.6%, respectively. North America was essentially flat at 0.2% growth, while EMEA and China declined on both reported and constant-currency bases.

Profitability was pressured despite the sales growth. Gross profit margin was 77.7%, compared with 78.0% in the prior-year period. Management cited approximately 47 basis points of sales mix pressure, 22 basis points of higher other costs, 20 basis points from higher inventory write-downs and 9 basis points from self-manufacturing and sourcing costs, partially offset by 64 basis points of pricing benefits. Adjusted EBITDA was $166.6 million and adjusted EBITDA margin was 12.6%, down 120 basis points versus the second quarter of 2025.

GAAP earnings were affected by refinancing-related costs. Herbalife recorded a $94.6 million loss on extinguishment of debt related to the 2024 Credit Facility and the 2029 Secured Notes, producing net loss attributable to Herbalife of $ (26.3) million and diluted loss per share of $ (0.25). Excluding specified adjustments, adjusted net income was $53.3 million and adjusted diluted EPS was $0.51. Operating cash flow was $32.9 million in the quarter and $146.7 million in the first six months. The company repurchased $10.0 million of shares in the first half, while net debt was $1,669.1 million at June 30, 2026.

The outlook retains reported sales growth for the remainder of the year but reflects a greater foreign-exchange burden. Third-quarter reported net sales growth is guided at +0.5% to +4.5% year-over-year, versus +1.5% to +5.5% on a constant currency basis. Full-year reported net-sales guidance was tightened to +2.5% to +5.5%, while constant-currency net-sales guidance was raised to +2.5% to +5.5%. Full-year reported adjusted EBITDA guidance was lowered to $670 million to $690 million from $675 million to $705 million, primarily reflecting FX headwinds, although constant-currency adjusted EBITDA guidance was increased to $690 million to $710 million.

Strategically, the company is expanding personalized nutrition through Bioniq GO, updates to the Pro2col™ platform and a limited beta of at-home blood biomarker diagnostics. The launches of Helio and Activate Energy broaden the Life I/O healthy lifespan offering. Investors will also monitor execution during the CFO transition: Scott Schaefer will succeed John DeSimone effective January 1, 2027, after DeSimone's retirement effective December 31, 2026.

Management, verbatim

Our net sales and EBITDA results for the second quarter were at the high end of previously issued guidance. While the recent strengthening of the U.S. dollar has resulted in additional foreign exchange headwinds affecting our reported outlook for the back half of the year, our constant currency outlook remains consistent with the expectations we shared last quarter.

John DeSimone, Chief Financial Officer

We delivered a fourth consecutive quarter of year-over-year net sales growth, and we continue to expect net sales growth for the remainder of the year. This momentum reflects the resilience of Herbalife and has us poised to successfully carry out our long-term growth strategy. John DeSimone played an impactful role in laying this foundation, and I am grateful to him for his leadership and partnership. I am confident Scott Schaefer’s financial expertise and strategic perspective will help propel us in our next chapter.

Stephan Gratziani

Not in the filing

stated, not guessed
  • Free cash flow was not reported.
  • Dividend amount and dividend declaration were not reported.
  • GAAP effective tax rate was not reported.
  • Third-quarter and full-year gross-margin guidance were not reported.
  • Third-quarter and full-year operating-expense guidance were not reported.
  • A separate previous-release outlook was not provided; therefore, no actual-versus-prior-guidance comparison is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about HLF earnings dates

When is Herbalife's next earnings date?
AlphAI has no date for HLF yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.